Medtronic plc (MDT) research: valuation against peers, fundamentals over time, risk and news coverage
Only 1 resolved forecast on record — below the 6-period threshold, so no verdict is published.
n = 1 resolved forecast · FY 2024 to FY 2024 · 3 still outstanding
Insufficient sample — no verdict published. MDT has 1 resolved forecast on record, below the 6 needed before we will characterise a management team’s forecasting. The record below is published in full; the company is excluded from every ranking on this site until it clears the threshold.
Next report expected 17 Nov 2026 (Q2 FY2027) — Estimated from the issuer's own filing history: FY2026Q2 results were released on 2025-11-18. source
| Period | Measure | Guided | Issued | Reported | Landed | Deviation | Verdict | Sources |
|---|---|---|---|---|---|---|---|---|
| FY 2027revised | EPS (adj.) | $5.94–$6.00 | 2026-09-01 | — | — | — | PENDING | guidance |
| “The company also raised its FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00 versus the prior $5.90 to $6.00.” | ||||||||
| FY 2027 | EPS (adj.) | $5.90–$6.00 | 2026-06-03 | — | — | — | PENDING | guidance |
| “The company is guiding to FY27 diluted non-GAAP EPS in the range of $5.90 to $6.00, representing FY27 diluted non-GAAP EPS growth in the range of 6.7% to 8.5%.” | ||||||||
| FY 2026revised | EPS (adj.) | $5.50–$5.54 | 2026-03-24 | — | — | — | PENDING | guidance |
| “Medtronic announced that it now expects non-GAAP earnings per share (EPS) for fiscal year 2026 to be in the range of $5.50 to $5.54, a revision from the Q3 earnings call EPS guidance of $5.62 to $5.66.” | ||||||||
| FY 2026revised | EPS (adj.) | $5.62–$5.66 | 2026-02-17 | — | — | — | PENDING | guidance |
| “The company reiterates its FY26 organic revenue growth of approximately 5.5% and diluted non-GAAP EPS guidance of $5.62 to $5.66.” | ||||||||
| FY 2026revised | EPS (adj.) | $5.62–$5.66 | 2025-11-18 | — | — | — | PENDING | guidance |
| “The company raised its FY26 diluted non-GAAP EPS guidance to the new range of $5.62 to $5.66 versus the prior $5.60 to $5.66.” | ||||||||
| FY 2026revised | EPS (adj.) | $5.60–$5.66 | 2025-08-19 | — | — | — | PENDING | guidance |
| “Medtronic is raising its FY26 diluted non-GAAP EPS guidance to the new range of $5.60 to $5.66 versus the prior range of $5.50 to $5.60.” | ||||||||
| FY 2026 | EPS (adj.) | $5.50–$5.60 | 2025-05-21 | — | — | — | PENDING | guidance |
| “Medtronic is guiding FY26 diluted non-GAAP EPS in the range of $5.50 to $5.60.” | ||||||||
| FY 2025revised | EPS (adj.) | $5.44–$5.50 | 2025-02-18 | — | — | — | PENDING | guidance |
| “The company continues to expect FY25 diluted non-GAAP EPS in the range of $5.44 to $5.50.” | ||||||||
| FY 2025revised | EPS (adj.) | $5.44–$5.50 | 2024-11-19 | — | — | — | PENDING | guidance |
| “The company raised its FY25 diluted non-GAAP EPS guidance to the new range of $5.44 to $5.50 versus the prior $5.42 to $5.50.” | ||||||||
| FY 2025revised | EPS (adj.) | $5.42–$5.50 | 2024-08-20 | — | — | — | PENDING | guidance |
| “The company raised its FY25 diluted non-GAAP EPS guidance to the new range of $5.42 to $5.50 versus the prior $5.40 to $5.50.” | ||||||||
| FY 2025 | EPS (adj.) | $5.40–$5.50 | 2024-05-23 | — | — | — | PENDING | guidance |
| “The company is guiding to FY25 diluted non-GAAP EPS in the range of $5.40 to $5.50, including an estimated 5% unfavorable impact from foreign currency exchange based on recent rates.” | ||||||||
| FY 2024revised | EPS (adj.) | $5.19–$5.21 | 2024-02-20 | $1.46 | −71.7% | BELOW | guidance · result | |
| “The company increased its FY24 diluted non-GAAP EPS guidance from the prior range of $5.13 to $5.19 to the new range of $5.19 to $5.21, a 4 cent increase at the midpoint that is reflective of the company’s third quarter outperformance.” | ||||||||
| FY 2024revised | EPS (adj.) | $5.13–$5.19 | 2023-11-21 | $1.46 | −71.1% | BELOW | guidance · result | |
| “The company increased its FY24 diluted non-GAAP EPS guidance from the prior range of $5.08 to $5.16 to the new range of $5.13 to $5.19, a 4 cent increase at the midpoint.” | ||||||||
| FY 2024revised | EPS (adj.) | $5.08–$5.16 | 2023-08-22 | $1.46 | −70.7% | BELOW | guidance · result | |
| “The company increased its FY24 diluted non-GAAP EPS guidance from the prior range of $5.00 to $5.10 to the new range of $5.08 to $5.16, a 7 cent increase at the midpoint, inline with the company’s operational EPS outperformance in the first quarter.” | ||||||||
| FY 2024 | EPS (adj.) | $5.00–$5.10 | 2023-05-25 | $1.46 | −70.1% | BELOW | guidance · result | |
| “The company is guiding to fiscal year 2024 non-GAAP EPS in the range of $5.00 to $5.10, including an estimated 6% unfavorable impact from foreign currency exchange rates at the beginning of May.” | ||||||||
Every figure above is read from the company’s own filings. “Guidance” links to the 8-K exhibit that issued the forecast; “result” links to the exhibit in which the company reported the outcome. Nothing here is an analyst estimate. How this is measured.
MDT
Medtronic plcNo data in this window.
Every report in our own archive tagged with this symbol, newest first — fetched from the archive alongside the market data.
Nothing filed on MDT yet. Search the archive for related coverage.
Full archive search for MDTEvery figure on this page is fetched and computed in your browser from free public sources — end-of-day prices and reported financials from Yahoo Finance's open endpoints, and our own archive for the coverage panel. Fundamental history on the free tier runs about four fiscal years and five quarters. Data is best-effort and unaudited; this is market research, not investment advice.